An Open-Label Study of CK-3773274 for Patients with Symptomatic Hypertrophic Cardiomyopathy (HCM)

Go Back to All Clinical Trials

An Open-Label Study of CK-3773274 for Patients with Symptomatic Hypertrophic Cardiomyopathy (HCM)

Brief description of study

HCM is a condition in which the heart muscle becomes abnormally thickened, which can sometimes block the blood flow out of the heart, and the heart muscle works harder to pump blood to the body (increased heart pumping function). Some participants with HCM have obstructive HCM (oHCM) and other participants have non-obstructive HCM (nHCM). The purpose of this study is to determine the safety and long-term effects of CK-3773274 and to learn how well it is tolerated at different, increasing dose levels in participants with HCM and if it causes any side effects. The study drug may reduce symptoms of your HCM by reducing heart pumping function. CK-3773274 is an investigational study drug in this study because it has not been approved by the U.S. Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States.

Clinical Study Identifier: s22-00565

ClinicalTrials.gov Identifier: NCTTX1797

Principal Investigator: Mark V. Sherrid.

Other Investigators: Daniele Massera, Woon Yee Wu, Maria Reuter.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies